The risk of hair loss in patients taking GLP-1 drugs, while low, is higher than with other diabetes drugs, new studies suggest.

Has a wanted fugitive been posing as a biotech executive? And what does it take to develop a therapy for an ultra-rare ...

Eli Lilly will seek regulatory approval for retatrutide, a powerful weight loss drug that a new study shows helped people lose nearly 56 pounds on average.

Eli Lilly (LLY +2.15%) has spent the past two years reinvesting the cash flow from its spectacularly successful GLP-1 drug into building out its pipeline, and it just made a diver ...

Eli Lilly is set for another win in the glucagon-like peptide-1 (GLP-1) sector as its triple-g agonist, retatrutide, has succeeded in type 2 diabetes and obesity. Marking the four ...

By Deena Beasley July 23 (Reuters) - Eli Lilly said on Thursday that two more Phase 3 trials of its experimental obesity drug ...

Eli Lilly and Co. LLY on Thursday reported topline results from two pivotal Phase 3 trials for its investigational ...

Eli Lilly & Co.’s highly anticipated next-generation weight-loss shot didn’t increase overall heart risk in a new study, the ...

Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two ...

A $2.5 billion settlement with Amazon Prime is in the works, a pharmaceutical company accuses another of false advertising ...

There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of ...

Comcast reported a lower profit in the second quarter, but narrowed subscriber losses in its domestic residential-broadband business for the second quarter in a row. Lockheed Martin Raises Full-Year ...